Publications in collaboration with researchers from Institute Catalá Oncología (12)

2024

  1. Encorafenib and binimetinib followed by radiotherapy for patients with BRAFV600-mutant melanoma and brain metastases (E-BRAIN/GEM1802 phase II study)

    Neuro-oncology, Vol. 26, Núm. 11, pp. 2074-2083

2022

  1. High-dose radiotherapy and risk-adapted androgen deprivation in localised prostate cancer (DART 01/05): 10-year results of a phase 3 randomised, controlled trial

    The Lancet Oncology, Vol. 23, Núm. 5, pp. 671-681

  2. Paclitaxel Plus Cetuximab as Induction Chemotherapy for Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Unfit for Cisplatin-Based Chemotherapy

    Frontiers in Oncology, Vol. 12

2021

  1. 10-Year Results of a Phase III Randomized Trial of High-Dose Radiotherapy and Risk-Adapted Androgen Deprivation in Localized Prostate Cancer

    International journal of radiation oncology, biology, physics, Vol. 111, Núm. 3, pp. S77

  2. Prognostic value of testosterone castration levels following androgen deprivation and high-dose radiotherapy in localized prostate cancer: Results from a phase III trial

    Radiotherapy and Oncology, Vol. 160, pp. 115-119

2020

  1. GOECP/SEOR clinical recommendations for lung cancer radiotherapy during the COVID-19 pandemic

    WORLD JOURNAL OF CLINICAL ONCOLOGY, Vol. 11, Núm. 8

2019

  1. Are there enough radiation oncologists to lead the new Spanish radiotherapy?

    Clinical and Translational Oncology, Vol. 21, Núm. 12, pp. 1663-1672

2016

  1. Late Radiation and Cardiovascular Adverse Effects After Androgen Deprivation and High-Dose Radiation Therapy in Prostate Cancer: Results From the DART 01/05 Randomized Phase 3 Trial

    International Journal of Radiation Oncology Biology Physics, Vol. 96, Núm. 2, pp. 341-348

2015

  1. Androgen deprivation and radiotherapy in patients with prostate cancer and cardiovascular risk factors: clinical controversies

    Clinical and Translational Oncology, Vol. 17, Núm. 3, pp. 223-229

  2. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): A randomised, controlled, phase 3 trial

    The Lancet Oncology, Vol. 16, Núm. 3, pp. 320-327

  3. Nomogramme für die Prognose eines biochemischen Rezidivs beim Prostatakarzinom nach Strahlentherapie und Androgendeprivationstherapie

    Strahlentherapie und Onkologie, Vol. 191, Núm. 10, pp. 792-800

2013

  1. Randomized phase II trial of non-platinum induction or consolidation chemotherapy plus concomitant chemoradiation in stage III NSCLC patients: Mature results of the Spanish Lung Cancer Group 0008 study

    Lung Cancer, Vol. 81, Núm. 1, pp. 84-90